SOURCE: Advanced fPAT Imaging Inc.

Advanced fPAT Imaging Inc.

June 02, 2015 06:00 ET

Advanced fPAT Imaging Announces Clinical First for the JBI-360™ Breast Imaging System

GAINESVILLE, FL--(Marketwired - June 02, 2015) - Advanced fPAT Imaging Inc. (AFPII), a new medical device company focused on early detection of breast cancer and now disease staging, announced today that its JBI-360 breast imaging system was able to track the metabolic effects of chemotherapy on a breast tumor during treatment. The JBI-360 uses an exciting new technology called 'Functional PhotoAcoustic Tomography' (fPAT) to create maps of key physiological markers within the breast. A research team led by Dr. Huabei Jiang, AFPII's Chief Science Advisor and inventor of the fPAT technique, demonstrated the JBI-360's capabilities in a pilot clinical study conducted at the University of Florida.

The JBI-360 employs a unique combination of low energy laser scanning and specially-designed high-resolution ultrasound detection technology (patent pending) to identify and quantify concentrations of both Hemoglobin and Oxygen Saturation within breast tissue. Hemoglobin and Oxygen Saturation are key physiological tissue markers which can be used for tumor location, identification, cellular activity levels, and sizing. Unlike x-ray mammography, which loses sensitivity with increasing breast tissue density, the JBI-360's fPAT technique is not affected by dense breast tissue.

In a case study that used the JBI-360 to monitor the results of chemotherapy on a patient with invasive mammary carcinoma and high-grade ductal carcinoma in-situ (DCIS), the fPAT images created by the JBI-360 clearly showed the change of total hemoglobin and oxygen saturation in the area of the tumor during the treatment period. The JBI-360 indicated a 60% reduction in the size of the tumor region.

According to AFPII's CEO Michael Addley, "This clinical result shows the potential of the JBI-360 as a new real-time tumor monitoring tool that allows the oncologist and the radiologist to continually interrogate the physiology of a tumor without subjecting the patient to the potential hazards of repeated radiation exposure. Clinicians may now monitor treatment results and adjust treatment protocols based upon tumor progression or regression during chemotherapy without requiring the patient to undergo painful breast compression or injections of contrast agents. As a 30-year medical device executive who has participated in the launches of several game-changing medical technologies, including CT and MRI, I am amazed at what Dr. Jiang's new imaging technique can do, and I am excited about the future of non-radiation based fPAT imaging!"

Diagnostic imaging is a $32 billion marketplace worldwide and is expected to grow to $49 billion by 2020. The company is currently seeking funding to commercialize the JBI-360 and welcomes any inquiries from potential investors.

Visit us at www.afpii.com

Image Available: http://www.marketwire.com/library/MwGo/2015/6/1/11G043396/Images/fPATChemoTracking-817753292980.jpg

Contact Information

  • For investment information, contact:
    Michael Addley
    CEO
    Email contact(954) 338-4635